After more than 15 years, the battle between the Canada Revenue Agency and Glaxo Canada over the transfer price for ranitidine—the active pharmaceutical ingredient used to make the branded, anti-ulcer drug Zantac—finally reached the Supreme Court of Canada (SCC) last month.
CRA strengthens its Transfer Pricing Practice
“We are excited to welcome Arin to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has more than three decades of...